STOCK TITAN

SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 3:30 pm ET. The event will be held virtually, and a video webcast can be accessed through the company’s Investors & Media page. SpringWorks specializes in developing medicines for severe rare diseases and cancer, with 16 development programs and two advanced product candidates in late-stage clinical trials. For further details, visit SpringWorks’ website.

Positive
  • None.
Negative
  • None.

STAMFORD, Conn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, November 30, 2021, at 3:30 pm ET.

A video webcast will be available on the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology portfolio of small molecule product candidates and is advancing 16 development programs, including two potentially registrational clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to expand its portfolio and create more solutions for patients with cancer. For more information, visit http://www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.

SpringWorks Contact:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: (203) 561-1646
Email: kdiamond@springworkstx.com


FAQ

When is SpringWorks Therapeutics participating in the Evercore ISI HealthCONx Conference?

SpringWorks Therapeutics will participate in the Evercore ISI HealthCONx Conference on November 30, 2021, at 3:30 pm ET.

How can I watch the SpringWorks Therapeutics Fireside Chat?

You can watch the SpringWorks Therapeutics Fireside Chat via a video webcast available on the Events & Presentations page of their Investors & Media section.

What is the focus of SpringWorks Therapeutics?

SpringWorks Therapeutics focuses on developing life-changing medicines for patients with severe rare diseases and cancer.

How many development programs does SpringWorks Therapeutics have?

SpringWorks Therapeutics is advancing 16 development programs, including two in late-stage clinical trials.

What is the stock symbol for SpringWorks Therapeutics?

The stock symbol for SpringWorks Therapeutics is SWTX.

SpringWorks Therapeutics, Inc.

NASDAQ:SWTX

SWTX Rankings

SWTX Latest News

SWTX Stock Data

2.57B
70.75M
1.92%
116.49%
16.52%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
STAMFORD